Sept. 12 Preclinical Quick Takes: Stephen Quake newco reveals epigenomic platform; plus Personal Genome, Summit and Biolife4D

Bluestar’s epigenomic platform IDs breast, pancreatic cancer
Bluestar Genomics Inc. (San Francisco, Calif.) showed it correctly identified breast and pancreatic cancers with areas under the curve of 0.89 and 0.95, respectively, with its machine learning algorithms that

Read the full 367 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers